George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.35
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (7.692%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.35
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Price Monitoring Extn

4 Aug 2021 16:41

RNS Number : 6116H
Shield Therapeutics PLC
04 August 2021
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APMDZGGRKDMGMZM

Date   Source Headline
31st Oct 20227:00 amRNSRepublic of Korea update
27th Oct 20227:00 amRNSShelf-life for Accrufer® extended to 48 months
24th Oct 20227:00 amRNSData presented at ACG Annual Scientific Meeting
30th Sep 20227:00 amRNSBlock Listing 6 Monthly Return
15th Sep 20221:52 pmEQSHardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building
14th Sep 20222:17 pmRNSHolding(s) in Company
8th Sep 20227:00 amRNSHalf-year Report
1st Sep 20222:20 pmRNSHolding(s) in Company
1st Sep 20227:00 amRNSLaunch of new corporate brand and website
31st Aug 20222:00 pmRNSTotal Voting Rights Update
31st Aug 202211:00 amRNSNotice of Interim Results
30th Aug 20229:30 amRNSHolding(s) in Company
12th Aug 202211:45 amEQSHardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous
9th Aug 20224:45 pmRNSGrant of share options
1st Aug 20227:00 amRNSCompletion of Loan Agreement & Partial Conversion
27th Jul 20224:20 pmRNSResults of 2022 General Meeting
27th Jul 20224:15 pmRNSResults of 2022 Annual General Meeting
26th Jul 20227:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US
14th Jul 20227:00 amRNSNew Drug Submission accepted by Health Canada
8th Jul 20227:00 amRNSNotice of General Meeting
30th Jun 20224:41 pmRNSSecond Price Monitoring Extn
30th Jun 20224:36 pmRNSPrice Monitoring Extension
30th Jun 20222:06 pmRNSSecond Price Monitoring Extn
30th Jun 20222:00 pmRNSPrice Monitoring Extension
30th Jun 202211:05 amRNSSecond Price Monitoring Extn
30th Jun 202211:00 amRNSPrice Monitoring Extension
30th Jun 20229:05 amRNSSecond Price Monitoring Extn
30th Jun 20229:00 amRNSPrice Monitoring Extension
30th Jun 20227:01 amRNS2021 Annual Report and 2022 AGM Notice
30th Jun 20227:00 amRNSBusiness Update, Final Results&Financing Agreement
29th Jun 20227:00 amRNSNotice of Results
28th Jun 20224:40 pmRNSSecond Price Monitoring Extn
28th Jun 20224:35 pmRNSPrice Monitoring Extension
28th Jun 20222:05 pmRNSSecond Price Monitoring Extn
28th Jun 20222:00 pmRNSPrice Monitoring Extension
29th Apr 20227:00 amRNSTotal Voting Rights Update
31st Mar 20223:50 pmRNSBlock Listing 6 Monthly Return
31st Mar 20223:50 pmRNSBlock Listing Application
21st Mar 20227:00 amRNSKYE Pharmaceuticals Files Accrufer® NDS in Canada
2nd Mar 20221:30 pmEQSHardman & Co Research: Shield Therapeutics (STX) - PBMs have bought in to Accrufer
25th Feb 20227:00 amRNSInvestor Presentation
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
23rd Feb 202211:05 amRNSSecond Price Monitoring Extn
23rd Feb 202211:00 amRNSPrice Monitoring Extension
18th Feb 20222:06 pmRNSSecond Price Monitoring Extn
18th Feb 20222:00 pmRNSPrice Monitoring Extension
17th Feb 20229:05 amRNSSecond Price Monitoring Extn
17th Feb 20229:00 amRNSPrice Monitoring Extension
17th Feb 20227:00 amRNSFull Year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.